A blue ribbon delegation, composed of representatives from the offices of the Secretary of Health of Mexico, the Commission for the Protection against Sanitary Risk (COFEPRIS) — the equivalent of the U.S. FDA in Mexico — and The National Institute of Public Health Mexico (INSP) — the equivalent of the U.S. NIH in Mexico — recently spent two days in Houston and College Station. The purpose of their trip was to meet with leading researchers and doctors to explore the latest regenerative medicine advancements, specifically those using autologous mesenchymal stem cells. The visit was initiated by David Eller, CEO of Houston-based biotechnology company Celltex Therapeutics Corporation.
“We were honored to host these esteemed experts, who came to Houston to learn about our company,” says Eller. “We are excited about their expressed interest in establishing shared relationships with Celltex and other leaders in their respective fields who are using autologous stem cells to initiate technological breakthroughs in the accelerating field of regenerative medicine.”
The delegation met with Dr. Darwin J. Prockop, Director of the Institute for Regenerative Medicine, Texas A&M College of Medicine – Texas A&M University; Dr. Philip A. Salem, a physician, researcher, educator and international statesman in cancer medicine, and President of Salem Oncology Center in Houston; Dr. Mark Adickes, Chief of the Division of Sports Medicine at Baylor College of Medicine; Dr. Stanley Jones, Celltex Chief Medical Officer and Dr. Jane Young, Celltex Chief Scientific Officer, as well as other researchers from Houston’s regenerative medicine community.
About Celltex Therapeutics Corporation
Celltex uses proprietary technology that isolates, multiplies and banks autologous (one’s own) adult mesenchymal stem cells (MSCs), to be used in regenerative therapy for injuries and chronic pain as well as a number of other conditions, including vascular, degenerative and autoimmune diseases. The Houston-based biotechnology company operates in a state-of-the-art laboratory compliant with Current Good Manufacturing Practice (cGMP) standards as recommended by the U.S. Food and Drug Administration (FDA) for the manufacturing of biological products.